Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Percentage of participants reporting each solicited administration site event |
The solicited administration site events are pain, redness and swelling. |
Within 7 days after the first study intervention dose (administered at Day 1) |
|
Primary |
Percentage of participants reporting each solicited administration site event |
The solicited administration site events are pain, redness and swelling. |
Within 7 days after the second study intervention dose (administered at Day 29) |
|
Primary |
Percentage of participants reporting each solicited systemic event |
The solicited systemic events are fever, fatigue, headache, myalgia and arthralgia. The preferred location for measuring temperature is the oral cavity. Fever is defined as temperature equal to or above (=) 38.0 degree Celsius (°C)/ 100.4 degree Fahrenheit (°F), regardless the location of measurement. |
Within 7 days after the first study intervention dose (administered at Day 1) |
|
Primary |
Percentage of participants reporting each solicited systemic event |
The solicited systemic events are fever, fatigue, headache, myalgia and arthralgia. The preferred location for measuring temperature is the oral cavity. Fever is defined as temperature equal to or above (=) 38.0 degree Celsius (°C)/ 100.4 degree Fahrenheit (°F), regardless the location of measurement. |
Within 7 days after the second study intervention dose (administered at Day 29) |
|
Primary |
Percentage of participants reporting unsolicited adverse events (AEs) |
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms (7 days after each dose) is reported as an unsolicited AE. |
Within 28 days after the first study intervention dose (administered at Day 1) |
|
Primary |
Percentage of participants reporting unsolicited adverse events (AEs) |
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms (7 days after each dose) is reported as an unsolicited AE. |
Within 28 days after the second study intervention dose (administered at Day 29) |
|
Primary |
Percentage of participants reporting medically attended events (MAEs) |
An MAE is an unsolicited AE for which the participants received medical attention defined as any symptoms or illnesses requiring hospitalization, or an emergency room visit, or visit to/by healthcare professionals. |
From Dose 1 (Day 1) up 12 months after last study intervention administration (Day 394) |
|
Primary |
Percentage of participants reporting any serious adverse events (SAEs) |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes. |
From Dose 1 (Day 1) up to 12 months after last study intervention administration (Day 394) |
|
Primary |
Percentage of participants reporting any potential immune-mediated disease (pIMDs) (classified as newly diagnosed or exacerbation of pre-existing events) |
PIMDs are a subset of adverse events of special interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. |
From Dose 1 (Day 1) up to 12 months after last study intervention administration (Day 394) |
|
Primary |
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at pre-study intervention administration (Day 1) in Part I of the study |
Clinically significant haematological and biochemical abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. |
At pre-study intervention administration (Day 1) |
|
Primary |
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 8 in Part I of the study |
|
At Day 8 |
|
Primary |
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 29 in Part I of the study |
|
At Day 29 |
|
Primary |
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 36 in Part I of the study |
|
At Day 36 |
|
Primary |
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 64 in Part I of the study |
|
At Day 64 |
|
Primary |
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at pre-study intervention administration (Day 1) in Part II of the study |
|
At pre-study intervention administration (Day 1) |
|
Primary |
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 8 in Part II of the study |
|
At Day 8 |
|
Primary |
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 29 in part II of the study |
|
At Day 29 |
|
Primary |
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 36 in Part II of the study |
|
At Day 36 |
|
Primary |
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 57 in Part II of the study |
|
At Day 57 |
|
Primary |
Time-to-first confirmed HSV-2 RGH episode in Part II of the study |
A suspected RGH episode will be classified as confirmed HSV-2 RGH episode if at least one of the lesional or anogenital swabs taken during the concerned episode is positive for HSV-2 as measured by PCR. |
14 days post-Dose 2 (Day 43) to Day 759 |
|
Secondary |
Number of confirmed HSV-2 RGH episodes in Part II of the study |
A suspected RGH episode will be classified as confirmed HSV-2 RGH episode if at least one of the lesional or anogenital swabs taken during the concerned episode is positive for HSV-2 as measured by PCR. |
14 days post-Dose 2 (Day 43) to Day 759 |
|
Secondary |
Percentage of participants free from confirmed HSV-2 RGH episode in Part II of the study |
A suspected RGH episode will be classified as confirmed HSV-2 RGH episode if at least one of the lesional or anogenital swabs taken during the concerned episode is positive for HSV-2 as measured by PCR. |
At 6, 12, 18 and 24 months after the last study intervention administration (Day 29) |
|
Secondary |
Herpes Symptoms Checklist (HSC) total score during each confirmed HSV-2 RGH episode in Part II of the study |
During genital herpes recurrences, participants are asked to complete the HSC, a 13-item checklist of herpes symptoms, where respondents record the severity of symptoms on a 4-point scale where 0 indicates no symptom and a higher point for more symptoms and severity. Total scores range from 0 (no symptom) to 39 (severe symptoms). At the onset of the genital herpes recurrence, this questionnaire is to be completed once daily, until no lesions or symptoms are present. |
14 days post-Dose 2 (Day 43) to Day 759 |
|
Secondary |
Number of days with RGH-associated symptoms during each confirmed HSV-2 RGH episode in Part II of the study |
Duration in days (i.e., number of days with RGH-associated symptoms) of each genital herpes recurrence is displayed by arm group. |
14 days post-Dose 2 (Day 43) to Day 759 |
|
Secondary |
Number of days with confirmed HSV-2 genital herpes lesions in Part II of the study |
Number of days on which lesions (swelling, blisters, sores, or crusts) are reported by the participant in the anogenital area during confirmed RGH episodes divided by the number of days of follow-up. |
14 days post-Dose 2 (Day 43) to Day 759 |
|
Secondary |
HSV-2 shedding rate reduction from baseline to 6 weeks post-Dose 2 (Day 71) in Part II of the study |
The HSV-2 shedding rate reduction is calculated as 1- (the HSV-2 shedding rate one month post-Dose 2 divided by the baseline HSV-2 shedding rate)*100. |
At 6 weeks post-Dose 2 (Day 71) compared to baseline (Day -28 to Day -1) |
|
Secondary |
HSV-2 shedding rate reduction from baseline to 6 months post-Dose 2 (Day 209) in Part II of the study |
The HSV-2 shedding rate reduction is calculated as 1 - (the HSV-2 shedding rate 6 months post-Dose 2 divided by the baseline HSV-2 shedding rate)*100. |
At 6 months post-Dose 2 (Day 209) compared to baseline (Day -28 to Day -1) |
|
Secondary |
HSV-2 shedding rate reduction from baseline to 12 months post-Dose 2 (Day 394) in Part II of the study |
The HSV-2 shedding rate reduction is calculated as 1 - (the HSV-2 shedding rate 12 months post-Dose 2 divided by the baseline HSV-2 shedding rate)*100. |
At 12 months post-Dose 2 (Day 394) compared to baseline (Day -28 to Day -1) |
|
Secondary |
HSV-2 shedding rate reduction from baseline to 24 months post-Dose 2 (Day 759) in Part II of the study |
The HSV-2 shedding rate reduction is calculated as 1 - (the HSV-2 shedding rate 24 months post-Dose 2 divided by the baseline HSV-2 shedding rate)*100. |
At 24 months post-Dose 2 (Day 759) compared to baseline (Day -28 to Day -1) |
|
Secondary |
Number of HSV-2 DNA shedding episodes in Part II of the study |
Number of HSV-2 shedding episodes during the 28-day swabbing period. |
Day -28 to Day -1 |
|
Secondary |
Number of HSV-2 DNA shedding episodes in Part II of the study |
Number of HSV-2 shedding episodes during the 28-day swabbing period. |
Day 43 to Day 70 |
|
Secondary |
Number of HSV-2 DNA shedding episodes in Part II of the study |
Number of HSV-2 shedding episodes during the 28-day swabbing period. |
Day 181 to Day 208 |
|
Secondary |
Number of HSV-2 DNA shedding episodes in Part II of the study |
Number of HSV-2 shedding episodes during the 28-day swabbing period. |
Day 366 to Day 393 |
|
Secondary |
Number of HSV-2 DNA shedding episodes in Part II of the study |
Number of HSV-2 shedding episodes during the 28-day swabbing period. |
Day 731 to Day 758 |
|
Secondary |
Duration of HSV-2 DNA shedding episodes in Part II of the study |
Number of days of a HSV-2 shedding episode. |
Day -28 to Day -1 |
|
Secondary |
Duration of HSV-2 DNA shedding episodes in Part II of the study |
Number of days of a HSV-2 shedding episode. |
Day 43 to Day 70 |
|
Secondary |
Duration of HSV-2 DNA shedding episodes in Part II of the study |
Number of days of a HSV-2 shedding episode. |
Day 181 to Day 208 |
|
Secondary |
Duration of HSV-2 DNA shedding episodes in Part II of the study |
Number of days of a HSV-2 shedding episode. |
Day 366 to Day 393 |
|
Secondary |
Duration of HSV-2 DNA shedding episodes in Part II of the study |
Number of days of a HSV-2 shedding episode. |
Day 731 to Day 758 |
|
Secondary |
Anti-HSVTI antibody geometric mean concentrations (GMCs) in Part I of the study |
|
At pre-study intervention administration (Day 1), Day 29, Day 64, Day 209 and Day 394 |
|
Secondary |
Anti-HSVTI antibody geometric mean concentrations (GMCs) in Part II of the study |
|
At pre-study intervention administration (Day 1), Day 29, Day 57, Day 209 and Day 394, Day 574, and Day 759 |
|
Secondary |
Percentage of seropositive participants for anti-HSVTI antibodies in Part I of the study |
|
At pre-study intervention administration (Day 1), Day 29, Day 64, Day 209 and Day 394 |
|
Secondary |
Percentage of seropositive participants for anti-HSVTI antibodies in Part II of the study |
|
At pre-study intervention administration (Day 1), Day 29, Day 57, Day 209 and Day 394, Day 574, and Day 759 |
|
Secondary |
Geometric mean of HSVTI-specific Cluster of Differentiation (CD)4+ T-cells frequency expressing at least two activation markers and including at least one cytokine in Part I of the study |
|
At pre-study intervention administration (Day 1), Day 29, Day 64, Day 209 and Day 394 |
|
Secondary |
Geometric mean of HSVTI-specific CD4+ T-cells frequency expressing at least 2 activation markers and including at least 1 cytokine in Part II of the study |
|
At pre-study intervention administration (Day 1), Day 29, Day 57, Day 209 and Day 394, Day 574, and Day 759 |
|
Secondary |
Geometric mean of HSVTI-specific CD8+ T-cells frequency expressing at least two activation markers and including at least one cytokine in Part I of the study |
|
At pre-study intervention administration (Day 1), Day 29, Day 64, Day 209 and Day 394 |
|
Secondary |
Geometric mean of HSVTI-specific CD8+ T-cells frequency expressing at least 2 activation markers and including at least 1 cytokine in Part II of the study |
|
At pre-study intervention administration (Day 1), Day 29, Day 57, Day 209 and Day 394, Day 574, and Day 759 |
|
Secondary |
Percentage of participants with a fatal SAE, SAE related to study intervention and potential immune-mediated disease (pIMDs) related to study intervention in Part II of the study |
A SAE related to study intervention is an SAE judged by the investigator as related to the study intervention. A fatal SAE is any untoward medical occurrence that results in death. |
From Dose 1 (Day 1) up to study end (Day 759) |
|